Background: Scientific data regarding effects of platelet transfusion on platelet count in dengue-related thrombocytopenia is scanty. Methods: A single center, randomized non-blinded trial was conducted on adult patients with dengue fever and platelet counts less than 30,000/μl. Patients were randomized to treatment and control group. Treatment group received single donor platelets. Patients with post-transfusion platelet increment (PPI) ≥10,000/μl and/or corrected count increment (CCI) ≥5,000/μl 1 h post-transfusion were considered responders. Primary outcome was platelet count increments at 24 and 72 h. Results:87 patients were enrolled, and 43 (48.2%) received platelet transfusion. Mean PPI and CCI at 1 h post-transfusion in the treatment group were 18,800/μl and 7,000/μl respectively. 22 (53.6%) patients in the treatment group were non-responders. Mean platelet increments at 24 and 72 h were higher in the treatment group as compared to the control group. Responders showed significantly higher increments when compared to non-responders and the control group at 24 h (p = 0.004 and p < 0.001, respectively) and 72 h (p = 0.001 and p < 0.001, respectively). Significant differences were found between non-responders and the control group at 24 h (p < 0.001), but not at 72 h (p = 0.104). Patients with lower baseline platelet count were more likely to be non-responders. Platelet transfusion neither prevented development of severe bleeding nor shortened time to cessation of bleeding. Three severe transfusion reactions and two deaths occurred in treatment group. Conclusion: In this trial, almost half the patients showed no response to a high-dose platelet transfusion. Platelet transfusion did not prevent development of severe bleeding or shorten time to cessation of bleeding and was associated with significant side effects. Therefore, platelet transfusion should not be routinely done in the management of dengue fever.

Keywords:
Dengue fever, Dengue hemorrhagic fever, Single donor apheresis platelets, Platelet transfusion, Corrected count increment, CCI, Transfusion reaction
1.
Kroeger A, Nathan M, Hombach J: World Health Organization TDR Reference Group on Dengue. Dengue. Nat Rev Microbiol 2004;2:360-361.
2.
Teixeira MG, Barreto ML: Diagnosis and management of dengue. BMJ 2009;339:b4338.
3.
Halstead SB: Dengue. Lancet 2007;370:1644-1652.
4.
WHO: Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Hemorrhagic Fever. Revised and Expanded Edition. World Health Organization, Regional Office for South-East Asia, 2011. www.searo.who.int/LinkFiles/Dengue_DHF_prevention and control_guidelines_rev.pdf.
5.
Nimmannitya S: Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Pub Hlth 1987;18(3):392-397.
6.
Mitrakul C, Poshyachinda M, Futrakul P, Sang-kawibha N, Ahandrik S: Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977;26:975-984.
7.
Mairuhu AT, Mac Gillavry MR, Setiati TE: Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis 2003;3:33-41.
8.
Krishnamurti C, Kalayanarooj S, Cutting MA, Peat RA, Rothwell SW, Reid TJ, Green S, Nisalak A, Endy TP, Vaughn DW, Nimmannitya S, Innis BL: Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 2001;65:840-847.
9.
Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905-909.
10.
Lye DC, Lee VJ, Sun Y, Leo YS: Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis 2009;48:1262-1265.
11.
Lum LC, Abdel-Latif Mel-A, Goh AY, Chan PW, Lam SK: Preventive transfusion in DSS - is it necessary? J Pediatr 2003;143:682-684.
12.
Chairulfatah A, Setiabudi D, Agoes R, Colebunders R: Thrombocytopenia and platelet transfusions in dengue haemorrhagic fever and dengue shock syndrome. Dengue Bull 2003;27.
13.
Payne BA, Pierre RV: Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984;59:123-125.
14.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
15.
Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS: Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006;19:127-132.
16.
Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-1538.
17.
Carr JM, Kruskall MS, Kaye JA, Robinson SH: Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986;80:1051-1054.
18.
The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
19.
Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-613.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.